Article Type
Review
Published
This review explores the mechanistic rationale and available evidence supporting the repurposing of apremilast in osteoarthritis, highlighting its potential to reduce pain and slow structural progression.
Review
This review explores the mechanistic rationale and available evidence supporting the repurposing of apremilast in osteoarthritis, highlighting its potential to reduce pain and slow structural progression.
Review
This narrative review explores new systemic therapies for psoriasis, including both approved and emerging biologics and small molecules, highlighting future directions in treatment.
Corrigendum
The authors wish to make the following corrections to their article: Magaña Serrano JA, Cigarroa López JA, Chávez Mendoza A, Ivey-Miranda JB, Mendoza Zavala GH, Olmos Domínguez L, Chávez Leal SA, Pombo Bartelt JE, Herrera-Garza EH, Mercado Leal G, Parra Michel R, Aguilera Mora LF, Nuriulu Escobar PL. Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts. Drugs Context. 2024;13:2023-8-1. https://doi.org/10.7573/dic.2023-8-1
Case Series
This collection of clinical experiences focuses on patients on siltuximab therapy, particularly regarding the idiopathic multicentric Castleman disease (iMCD) diagnostic work-up and treatment administration in patients with complex disease entering differential diagnosis with Castleman disease or with concomitant diseases.
Review
Heart failure (HF) represents a major healthcare problem, reaching epidemic figures worldwide. This article provides an update on the vulnerable period of HF with reduced ejection fraction (HFrEF) and recommendations are given regarding the management of HF during this phase.